|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Stephen R. Davis J.D.||CEO & Director||1,03M||N/D||1961|
|Dr. Srdjan R. Stankovic M.D., M.S.P.H.||Pres||933,1k||2,04M||1957|
|Mr. Mark C. Schneyer||Exec. VP & CFO||555,49k||N/D||1974|
|Mr. Brendan P. Teehan||Exec. VP, COO & Head of Commercial||486,47k||N/D||1969|
|Mr. Austin D. Kim||Exec. VP, Gen. Counsel & Sec.||559,24k||N/D||1964|
|Mr. James K. Kihara||VP, Chief Accounting Officer & Corp. Controller||N/D||N/D||1981|
|Mr. Bob Mischler||Sr. VP of Strategy & Technology Operations||N/D||N/D||N/D|
|Mr. Mark C. Johnson||VP of Investor Relations||N/D||N/D||N/D|
|Ms. Julie Fisher||Sr. VP of Marketing & Commercial Strategy||N/D||N/D||N/D|
|Ms. Holly Valdiviez||Sr. VP & Head of Sales||N/D||N/D||N/D|
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
L'ISS Governance QualityScore di ACADIA Pharmaceuticals Inc. al 31 luglio 2022 è 6. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 5; diritti degli azionisti: 8; retribuzione: 4.